Who Generates Higher Gross Profit? Supernus Pharmaceuticals, Inc. or BioCryst Pharmaceuticals, Inc.

Supernus vs. BioCryst: A Decade of Gross Profit Comparison

__timestampBioCryst Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 201413486000116287000
Thursday, January 1, 201546361000136004000
Friday, January 1, 201623654000203017000
Sunday, January 1, 201723484000287023000
Monday, January 1, 201820182000393541000
Tuesday, January 1, 201944734000376095000
Wednesday, January 1, 202016136000467938000
Friday, January 1, 2021149906000504714000
Saturday, January 1, 2022264233000580017000
Sunday, January 1, 2023326751000523742000
Loading chart...

Cracking the code

A Tale of Two Pharmaceuticals: Gross Profit Analysis

In the competitive world of pharmaceuticals, financial performance is a key indicator of a company's success. This analysis compares the gross profits of Supernus Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade, from 2014 to 2023. Supernus Pharmaceuticals consistently outperformed BioCryst Pharmaceuticals, with an average gross profit nearly four times higher. In 2022, Supernus reached its peak with a gross profit of approximately $580 million, while BioCryst's highest was around $327 million in 2023. This trend highlights Supernus's robust market strategy and operational efficiency. Despite BioCryst's significant growth, particularly from 2021 onwards, it still trails behind Supernus. This financial snapshot provides valuable insights into the strategic positioning and market dynamics of these two industry players, offering a glimpse into their future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025